This medical journal article provides a comprehensive overview of what is currently known about the immune effects of cryoablation in various cancer types. The “take home message” from the journal article is that we have just begun to “scratch the surface” in understanding the immune effects of cancer cryoablation and have much to do to harness and promote its immune benefits. Consequently, there is great need for a broader selection of cryoablation cancer clinical trials and an even greater need for patient participation in cryoablation cancer clinical research. It is also clear from the journal article that a robust, sustained, beneficial immune response to cryoablation will likely require use of pharmacological agents or other therapies that are capable of enhancing specific aspects of the natural immune response.
This medical journal article provides a comprehensive overview of the current state of affairs with breast cancer cryoablation, including a summary of published science, use of cryoablation in the management of both early stage and advanced breast cancer, and a brief discussion of breast imaging after cryoablation.
The article also discusses the irony that cryoablation trials have excluded ductal carcinoma in situ (DCIS) or stage 0 breast cancer, which is, in my opinion, the condition that is in greatest need of minimally invasive treatments. To meet this objective, I am now working on a new research study involving the use of cryoablation in the management of DCIS.